Cipher Pharmaceuticals Valuation

Is PHE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PHE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PHE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHE?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for PHE. This is calculated by dividing PHE's market cap by their current preferred multiple.
What is PHE's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

PHE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.9x
Enterprise Value/EBITDA	20.9x
PEG Ratio	1.1x

Price to Earnings Ratio vs Peers

How does PHE's PE Ratio compare to its peers?

The above table shows the PE ratio for PHE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	17.3x
PSG PharmaSGP Holding	16.6x	14.6%	€297.4m
2FJ0 Pierrel	29.9x	n/a	€92.8m
DMP Dermapharm Holding	22x	19.8%	€1.7b
93M1 MPH Health Care	0.8x	-65.7%	€98.5m
PHE Cipher Pharmaceuticals	14.6x	12.7%	€325.2m

Price-To-Earnings vs Peers: PHE is good value based on its Price-To-Earnings Ratio (14.6x) compared to the peer average (16.8x).

Price to Earnings Ratio vs Industry

How does PHE's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.5%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: PHE is good value based on its Price-To-Earnings Ratio (14.6x) compared to the European Pharmaceuticals industry average (21.2x).

Price to Earnings Ratio vs Fair Ratio

What is PHE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	14.6x
Fair PE Ratio	12.4x

Price-To-Earnings vs Fair Ratio: PHE is expensive based on its Price-To-Earnings Ratio (14.6x) compared to the estimated Fair Price-To-Earnings Ratio (12.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PHE forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€8.50	€11.20 +31.7%	10.1%	€12.47	€9.72	n/a	3
Nov ’25	€9.70	€11.28 +16.3%	10.9%	€12.73	€9.72	n/a	3
Oct ’25	€9.95	€10.77 +8.2%	7.3%	€11.32	€9.66	n/a	3
Sep ’25	€12.70	€10.54 -17.0%	6.5%	€11.32	€9.65	n/a	3
Aug ’25	€8.15	€9.13 +12.0%	22.8%	€11.35	€6.34	n/a	3
Jul ’25	€5.15	€7.24 +40.6%	8.0%	€7.81	€6.45	n/a	3
Jun ’25	€5.75	€7.24 +25.9%	8.0%	€7.81	€6.45	n/a	3
May ’25	€5.85	€5.17 -11.7%	19.9%	€6.28	€3.80	n/a	3
Apr ’25	€6.10	€5.17 -15.3%	19.9%	€6.28	€3.80	n/a	3
Mar ’25	€4.88	€4.55 -6.7%	15.3%	€5.51	€3.85	n/a	3
Feb ’25	€4.02	€3.78 -5.9%	11.1%	€4.27	€3.25	n/a	3
Jan ’25	€3.70	€3.70 -0.09%	9.6%	€4.07	€3.22	n/a	3
Dec ’24	€4.26	€3.70 -13.2%	9.6%	€4.07	€3.22	n/a	3
Nov ’24	€2.94	€2.94 +0.1%	7.2%	€3.23	€2.72	€9.70	3
Oct ’24	€2.92	€2.94 +0.8%	7.2%	€3.23	€2.72	€9.95	3
Sep ’24	€2.68	€2.94 +9.8%	7.2%	€3.23	€2.72	€12.70	3
Aug ’24	€2.46	€2.99 +21.7%	7.2%	€3.28	€2.76	€8.15	3
Jul ’24	€2.46	€2.99 +21.7%	7.2%	€3.28	€2.76	€5.15	3
Jun ’24	€2.64	€2.99 +13.4%	7.2%	€3.28	€2.76	€5.75	3
May ’24	€2.22	€2.82 +26.9%	3.0%	€2.90	€2.73	€5.85	2
Apr ’24	€2.22	€2.82 +27.2%	3.0%	€2.90	€2.73	€6.10	2
Mar ’24	€2.58	€2.84 +10.0%	3.0%	€2.93	€2.75	€4.88	2
Feb ’24	€2.30	€2.84 +23.7%	3.0%	€2.93	€2.75	€4.02	2
Jan ’24	€2.66	€3.00 +12.9%	3.0%	€3.09	€2.91	€3.70	2
Dec ’23	€2.39	€3.00 +25.6%	3.0%	€3.09	€2.91	€4.26	2
Nov ’23	€2.29	€2.52 +10.2%	6.1%	€2.67	€2.36	€2.94	2

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.